Skip to main content

Table 1 Demographic and clinical features at switch to dual therapy

From: Biochemical and inflammatory modifications after switching to dual antiretroviral therapy in HIV-infected patients in Italy: a multicenter retrospective cohort study from 2007 to 2015

Variables From tenofovir/emtricitabine n (%)
(n = 364)
From abacavir/lamivudine n (%)
(n = 65)
p-valuea
Male 249 (68.4) 52 (80.0) 0.060
Age, in years, mean (SD) 48.1 (10.2) 51.0 (10.4)  
 < 40 65 (17.9) 5 (7.7) 0.093
 40–49 145 (39.8) 26 (40.0)  
 ≥ 50 154 (42.3) 34 (52.3)  
Intravenous Drug Use 85 (27.6) 15 (25.9) 0.953
HCV co-infection 134 (36.8) 24 (36.9) 0.987
CD4 cell count, cell/mm3, mean (SD) 631.6 (295.6) 678.1 (342.2)  
 < 200 15 (4.9) 1 (1.8) 0.674
 200–349 35 (11.4) 8 (14.6)  
 350–499 51 (16.7) 8 (14.6)  
 ≥ 500 205 (67.0) 38 (69.1)  
Positive HIV-RNA, >  37 copies/mL 37 (12.3) 6 (11.3) 0.835
Time (months) in tenofovir/abacavir 110.0 (68.3) 110.4 (78.7) 0.970
Dual regimens:
 Atazanavir/r + 3TC (regimen 1) 121 (33.2) 17 (26.2) < 0.001
 Darunavir/r + 3TC (regimen 2) 84 (23.1) 14 (21.5)  
 Lopinavir/r + 3TC (regimen 3) 31 (8.5) 1 (1.5)  
 Raltegravir/dolutegravir+PI/r (regimen 4) 128 (35.2) 33 (50.8)  
Number of patients with at least one previous virological failure 79 (21.7) 25 (38.5) 0.004
  1. aWe used Student t-test for comparison of means Chi-squared test for comparition of proportions